Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Sonrotoclax by BeiGene for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Sonrotoclax is under clinical development by BeiGene and currently in Phase III for Chronic Lymphocytic Leukemia (CLL). According to GlobalData,...
Sonrotoclax by BeiGene for Refractory Multiple Myeloma: Likelihood of Approval
Sonrotoclax is under clinical development by BeiGene and currently in Phase II for Refractory Multiple Myeloma. According to GlobalData, Phase...
Sonrotoclax by BeiGene for Relapsed Multiple Myeloma: Likelihood of Approval
Sonrotoclax is under clinical development by BeiGene and currently in Phase II for Relapsed Multiple Myeloma. According to GlobalData, Phase...
Sonrotoclax by BeiGene for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma): Likelihood of Approval
Sonrotoclax is under clinical development by BeiGene and currently in Phase II for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According to GlobalData,...
Sonrotoclax by BeiGene for Mantle Cell Lymphoma: Likelihood of Approval
Sonrotoclax is under clinical development by BeiGene and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData, Phase...
Sonrotoclax by BeiGene for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Sonrotoclax is under clinical development by BeiGene and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)....
Sonrotoclax by BeiGene for Multiple Myeloma (Kahler Disease): Likelihood of Approval
Sonrotoclax is under clinical development by BeiGene and currently in Phase II for Multiple Myeloma (Kahler Disease). According to GlobalData,...
Risk adjusted net present value: What is the current valuation of BeiGene's Sonrotoclax?
Sonrotoclax is a small molecule commercialized by BeiGene, with a leading Phase III program in Chronic Lymphocytic Leukemia (CLL). According...